- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07588711
Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) as an Anti-inflammatory Strategy for the Treatment of Neuropathic Pain Following Spinal Cord Injury
Przegląd badań
Status
Szczegółowy opis
Neuropathic pain is a common and debilitating complication following spinal cord injury (SCI) and is frequently resistant to pharmacologic treatment. Chronic neuroinflammation and reduced vagal tone are increasingly recognized contributors to persistent neuropathic pain after SCI. The vagus nerve plays a central role in immune regulation and descending pain modulation.
Transcutaneous auricular vagus nerve stimulation (taVNS) is a noninvasive neuromodulation technique that stimulates vagal afferent fibers via the external ear. Prior Health Canada-authorized trials conducted by the investigative team have demonstrated the feasibility, safety, and autonomic effects of taVNS in individuals with SCI.
This single-site, randomized, double-blind, sham-controlled pilot study will enroll 32 adults with SCI and neuropathic pain. Participants will be randomized 1:1 to receive either active or sham taVNS for 4 hours per day over a 30-day home-based intervention period. Outcomes will be assessed at baseline and immediately post-intervention. Feasibility and safety outcomes are primary, while exploratory clinical and mechanistic outcomes will inform the design of a future definitive randomized controlled trial.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: David J Allison, PhD.
- Numer telefonu: 42570 519 646 6100
- E-mail: David.Allison@sjhc.london.on.ca
Kopia zapasowa kontaktu do badania
- Nazwa: Joy Jiang
- Numer telefonu: 42570 519 646 6100
- E-mail: fjiang63@uwo.ca
Lokalizacje studiów
-
-
Ontario
-
London, Ontario, Kanada, N6C0A7
- Parkwood Institute, St Joseph's Health Care London
-
Kontakt:
- Joy Jiang
- Numer telefonu: 42570 519 646 6100
- E-mail: fjiang63@uwo.ca
-
Kontakt:
- David J. Allison, PhD
- Numer telefonu: 42570 519 646 6100
- E-mail: David.Allison@sjhc.london.on.ca
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- SCI of any level or severity
- 18 years of age or older
- current neuropathic pain
- on no medications or on a stable prescribed dose (no change in prior 6-weeks) of anti-inflammatory, pain medications and/or depression medications
Exclusion Criteria:
- Prone to autonomic dysreflexia
- presence of cardiovascular disease
- pacemaker or other implanted electrical device
- cerebral shunts
- epilepsy
- pregnant or attempting to become pregnant
- current wound/infection
- unstable dose of prescribed anti-inflammatory, depression, or pain medications within past 6-weeks.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Active taVNS
Participants receive active transcutaneous auricular vagus nerve stimulation delivered via the cymba conchae of the left ear using the using the tVNS R device (taVNS Technologies, Erlangen, Germany) for 4 hours per day for 30 days.
|
Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany).
To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA (milliamps) until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA).
Pulse width will be set at 100μs (microseconds) and frequency will be set at 25Hz (Hertz).
Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
|
|
Pozorny komparator: Sham taVNS
Stimulation will target the ear lobe using the tVNS R device (taVNS Technologies, Erlangen, Germany) for 4 hours per day for 30 days.
Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
|
Stimulation will target the ear lobe using the tVNS R device (taVNS Technologies, Erlangen, Germany).
To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA).
Pulse width will be set at 100μs and frequency will be set at 25Hz.
Participants will perform 4 hours of stimulation per day for a period of 30 days.
Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Częstość występowania zdarzeń niepożądanych wynikających z leczenia podczas interwencji
Ramy czasowe: 30 dni
|
Wszystkie zdarzenia niepożądane, które wystąpią podczas interwencji, będą rejestrowane podczas rozmów telefonicznych i/lub wizyt badawczych odbywających się dwa razy w tygodniu i porównywane pomiędzy aktywnymi i pozorowanymi warunkami taVNS.
Rejestrowany będzie opis zdarzenia niepożądanego, liczba zdarzeń i całkowita liczba uczestników, których to dotyczy.
|
30 dni
|
|
Success of Participant and Investigator Blinding
Ramy czasowe: Day 30
|
Blinding success will be assessed after completion of the intervention by asking participants and investigators to indicate which treatment group they believe the participant was assigned to (active taVNS or sham taVNS).
Blinding effectiveness will be quantified using the James Blinding Index, calculated separately for participants and investigators.
Blinding outcomes will be summarized descriptively.
|
Day 30
|
|
Recruitment Rate and Time to Recruit Target Sample Size
Ramy czasowe: Up to 20 months
|
Recruitment feasibility will be assessed by documenting the number and proportion of eligible individuals who consent to participate and the total time required to recruit the target sample of 32 participants.
Recruitment rate will be calculated as the percentage of eligible candidates who agree to participate.
These data will be summarized descriptively for the overall study population.
|
Up to 20 months
|
|
Retention and Attrition During the 30-Day Intervention
Ramy czasowe: 30 days
|
Retention will be assessed as the proportion of enrolled participants who complete the full 30-day intervention and post-intervention assessment.
Attrition will be recorded as the number and proportion of participants who withdraw prior to study completion.
Reasons for withdrawal or loss to follow-up will be documented where available.
Retention and attrition rates will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
30 days
|
|
Adherence to Daily taVNS Stimulation Prescription
Ramy czasowe: 30 days
|
Adherence will be assessed using automated usage data recorded by the taVNS device and associated smartphone application.
Daily adherence will be calculated as the percentage of the prescribed 4-hour daily stimulation period completed (actual stimulation time divided by prescribed stimulation time × 100).
Overall adherence will be summarized as the mean daily adherence across the 30-day intervention period.
Adherence will be compared descriptively between the active taVNS and sham taVNS groups.
|
30 days
|
|
Acceptability with the taVNS intervention
Ramy czasowe: Day 30
|
Participant acceptability will be assessed at the end of the intervention using the Acceptability of Intervention Measure (AIM).
Acceptability scores will be summarized descriptively and compared between the active taVNS and sham taVNS conditions.
|
Day 30
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Circulating C-Reactive Protein
Ramy czasowe: Baseline and Day 30
|
Plasma concentrations of C-reactive protein (CRP) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in milligrams per liter (mg/L), with higher values indicating greater systemic inflammation.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interleukin-1 Beta
Ramy czasowe: Baseline and Day 30
|
Plasma concentrations of interleukin-1 beta (IL-1β) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interleukin-6
Ramy czasowe: Baseline and Day 30
|
Plasma concentrations of interleukin-6 (IL-6) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Interferon Gamma
Ramy czasowe: Baseline and Day 30
|
Plasma concentrations of interferon gamma (IFN-γ) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Circulating Tumor Necrosis Factor Alpha
Ramy czasowe: Baseline and Day 30
|
Plasma concentrations of tumor necrosis factor alpha (TNF-α) will be measured from fasting blood samples collected at baseline and at the end of the intervention.
Concentrations will be reported in picograms per milliliter (pg/mL), with higher values indicating greater pro-inflammatory activity.
Change values will be calculated as post-intervention values minus baseline values and summarized descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Neuropathic Pain Assessed by the Neuropathic Pain Symptoms Inventory
Ramy czasowe: Baseline and Day 30
|
Neuropathic pain severity and interference will be assessed using the Neuropathic Pain Symptoms Inventory (NPSI), a self-reported questionnaire with total scores ranging from 0 to 100, where higher scores indicate greater neuropathic pain severity and pain-related interference.
Change scores will be calculated as post-intervention values minus baseline values.
Mean changes and variability will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Neuropathic Pain Assessed by the International Spinal Cord Injury Pain Basic Data Set (version 3)
Ramy czasowe: Baseline and Day 30
|
Neuropathic pain severity and pain-related interference will be assessed using the International Spinal Cord Injury Pain Basic Data Set (ISCIPBDS), version 3, which includes numeric rating scales ranging from 0 to 10, where higher scores indicate greater pain intensity and greater pain-related interference.
Change scores will be calculated as post-intervention values minus baseline values.
Mean changes and variability will be summarized and compared descriptively between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Vagal Tone Assessed by Heart Rate Variability
Ramy czasowe: Baseline and Day 30
|
Vagal tone will be assessed using heart rate variability (HRV) derived from a 5-minute resting electrocardiogram recording.
Root mean square of successive differences (RMSSD) and high-frequency power will be calculated using standard HRV analysis procedures.
Change in HRV measures from baseline to post-intervention will be summarized descriptively and compared between the active taVNS and sham taVNS groups.
|
Baseline and Day 30
|
|
Change in Health-Related Quality of Life
Ramy czasowe: Baseline and Day 30
|
Quality of life will be assessed using selected short forms from the Spinal Cord Injury-Quality of Life (SCI-QOL) measurement system, including Pain Interference, Depression, and Positive Affect and Well-Being domains.
Scores will be calculated as standardized T-scores.
Change in quality-of-life scores from baseline to post-intervention will be summarized and compared descriptively between treatment groups.
|
Baseline and Day 30
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Ból
- Objawy neurologiczne
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Rany i urazy
- Procesy patologiczne
- Choroby nerwowo-mięśniowe
- Choroby obwodowego układu nerwowego
- Uraz, układ nerwowy
- Choroby rdzenia kręgowego
- Stany patologiczne, oznaki i objawy
- Objawy i symptomy
- Zapalenie
- Nerwoból
- Uszkodzenia rdzenia kręgowego
Inne numery identyfikacyjne badania
- ALLISON-03-2026
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .